Eli Lilly and Company (NYSE:LLY) Holdings Raised by Acropolis Investment Management LLC

Posted by on Mar 20th, 2023

Acropolis Investment Management LLC boosted its stake in Eli Lilly and Company (NYSE:LLY – Get Rating) by 12.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 606 shares of the company’s stock after buying an additional 67 shares during the quarter. Acropolis Investment Management LLC’s holdings in Eli Lilly and were worth $222,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bailard Inc. lifted its position in Eli Lilly and by 6.3% in the 3rd quarter. Bailard Inc. now owns 10,580 shares of the company’s stock worth $3,421,000 after buying an additional 627 shares in the last quarter. Inverness Counsel LLC NY raised its holdings in shares of Eli Lilly and by 3.0% during the 3rd quarter. Inverness Counsel LLC NY now owns 1,739 shares of the company’s stock valued at $562,000 after purchasing an additional 51 shares in the last quarter. Oxford Financial Group Ltd. raised its holdings in shares of Eli Lilly and by 6.5% during the 3rd quarter. Oxford Financial Group Ltd. now owns 185,296 shares of the company’s stock valued at $59,916,000 after purchasing an additional 11,362 shares in the last quarter. Centaurus Financial Inc. raised its holdings in shares of Eli Lilly and by 13.6% during the 3rd quarter. Centaurus Financial Inc. now owns 3,872 shares of the company’s stock valued at $1,252,000 after purchasing an additional 464 shares in the last quarter. Finally, GPS Wealth Strategies Group LLC raised its holdings in shares of Eli Lilly and by 8.4% during the 3rd quarter. GPS Wealth Strategies Group LLC now owns 515 shares of the company’s stock valued at $167,000 after purchasing an additional 40 shares in the last quarter. Hedge funds and other institutional investors own 82.13% of the company’s stock.

Eli Lilly and Price Performance

Shares of Eli Lilly and stock opened at $329.18 on Monday. The company has a debt-to-equity ratio of 1.37, a quick ratio of 0.80 and a current ratio of 1.05. The firm’s 50-day simple moving average is $335.87 and its 200-day simple moving average is $341.70. Eli Lilly and Company has a twelve month low of $276.83 and a twelve month high of $384.44. The firm has a market cap of $312.82 billion, a P/E ratio of 47.71, a price-to-earnings-growth ratio of 1.88 and a beta of 0.36.

Eli Lilly and (NYSE:LLY – Get Rating) last announced its earnings results on Thursday, February 2nd. The company reported $2.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.83 by $0.26. Eli Lilly and had a net margin of 21.88% and a return on equity of 73.61%. The company had revenue of $7.30 billion during the quarter, compared to the consensus estimate of $7.39 billion. During the same period in the previous year, the firm posted $2.49 earnings per share. The company’s revenue was down 8.7% on a year-over-year basis. As a group, research analysts expect that Eli Lilly and Company will post 8.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on LLY shares. StockNews.com started coverage on shares of Eli Lilly and in a report on Thursday. They set a “buy” rating on the stock. Wells Fargo & Company upgraded shares of Eli Lilly and from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $360.00 to $375.00 in a research note on Monday, March 13th. Cowen raised their target price on shares of Eli Lilly and from $390.00 to $430.00 in a research note on Monday, December 5th. SVB Leerink raised their target price on shares of Eli Lilly and from $384.00 to $410.00 and gave the company an “outperform” rating in a research note on Friday, December 16th. Finally, Guggenheim raised their target price on shares of Eli Lilly and from $399.00 to $401.00 and gave the company a “buy” rating in a research note on Wednesday, December 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $382.05.

Insiders Place Their Bets

In other Eli Lilly and news, EVP Anne E. White sold 2,500 shares of the business’s stock in a transaction dated Friday, February 10th. The shares were sold at an average price of $342.76, for a total value of $856,900.00. Following the completion of the transaction, the executive vice president now directly owns 60,426 shares of the company’s stock, valued at $20,711,615.76. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.12% of the company’s stock.

About Eli Lilly and

(Get Rating)

Eli Lilly & Co engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm’s products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Featured Stories

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.